Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
Trastuzumab
KAZIA THERAPEUTICS LTD
Breast Cancer
1 trial -
Trastuzumab
PUMA BIOTECHNOLOGY, INC.
Metastatic Colorectal Cancer
1 trial -
Trastuzumab
United Therapeutics Europe Ltd
Metastatic Colorectal Adenocarcinoma
1 trial -
Trastuzumab
United Therapeutics Europe Ltd
Metastatic Colon Adenocarcinoma
1 trial -
Trastuzumab deruxtecan
AstraZeneca
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
1 trial -
Trastuzumab in Combination with TS-ONE and cisplatin
Hospital Authority, Hong Kong
Gastric Cancer
1 trial -
Trilaciclib
The First People's Hospital of Lianyungang
Advanced Squamous Non-Small-Cell Lung Cancer
1 trial -
Trilaciclib
The First People's Hospital of Lianyungang
Osteosarcoma
1 trial -
Trilaciclib and Sacituzumab Tirumotecan
The First People's Hospital of Lianyungang
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences Pty Limited
Metastatic Solid Tumors
1 trial -
Tumor infiltrating lymphocytes (TIL) LN-145
Iovance Biotherapeutics B.V.
Metastatic Triple Negative Breast Cancer
1 trial -
Tunlametinib+PD-1 mAb
BEONE MEDICINES AUS PTY LTD
Gastric Adenocarcinoma
1 trial -
Tuspetinib
Aptose Biosciences
Leukemia, Myeloid, Acute
1 trial -
U1111-1305-0044
The George Institute
Early triple-negative breast cancer (TNBC)
1 trial -
UC-0107/1810
Ningbo Cancer Hospital
BRAF(V600) mutation-positive melanoma with brain metastasis (MBM)
1 trial -
UC-0110/1608
Ningbo Cancer Hospital
RAS and B-RAF wild-type metastatic colorectal cancer. RAS and B-RAF mutation will be determined using circulating cell-free DNA (ccfDNA) by IntPlex method
1 trial -
UC-0110/1719
Ningbo Cancer Hospital
Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy
1 trial -
UC-0140/1711_UCBG3
Ningbo Cancer Hospital
Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally recurrent (unresectable) or metastatic breast cancer.
1 trial -
UC-0140/1812
Ningbo Cancer Hospital
ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.
1 trial -
UC-0150/1704
Ningbo Cancer Hospital
Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).
1 trial -
UC-BCG-2011
Ningbo Cancer Hospital
HER2+ metastatic breast cancer with isolated brain progression
1 trial -
UC-BCG-2103
Ningbo Cancer Hospital
Post-menopausal women with localized luminal A breast cancer and considered at low risk of metastatic relapse
1 trial -
UC-BCG-2211, CAPPA
Ningbo Cancer Hospital
Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.
1 trial -
UC-BCG-2213
The George Institute
Triple negative breast cancer
1 trial -
UC-BCG-2312
Ningbo Cancer Hospital
Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy
1 trial -
UC-BCG-2513
Ningbo Cancer Hospital
Postmenopausal patients with small (pT1a-b pN0) hormone receptor positive (HR⁺) and HER2 negative (HER2⁻) early breast cancer with a Luminal A phenotype and at low risk of recurrence.
1 trial -
UC-GIG-2023
Ningbo Cancer Hospital
Patients with HER 2 negative locally advanced, recurrent or metastatic gastric, oesophagus or gastroesophageal junction adenocarcinoma
1 trial -
UC-GIG-2308
Ningbo Cancer Hospital
Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment
1 trial -
UC-GIG-2311
Ningbo Cancer Hospital
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication
1 trial -
UC-GIG-2404
Ningbo Cancer Hospital
Advanced biliary tract cancer (BTC)
1 trial -
UC-GIG-2411
Ningbo Cancer Hospital
Metastatic or locally advanced irresectable (stage IV) gastric cancer (GC) or esophagogastric junction cancer (EGJC), with and without actionable biomarker (HER2/Claudin18.2)
1 trial -
UC-GMP-2504
Ningbo Cancer Hospital
Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting
1 trial -
UC-IMM-2302
Ningbo Cancer Hospital
Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer
1 trial -
UC-IMM-2509/2510
Ningbo Cancer Hospital
NEOREM: Localized solid malignancies that are eligible to receive neo-adjuvant therapy and have medical unmet needs related to disease-free survival, overall survival or quality of life / NEO-1: Resectable stage III cutaneous or mucosal melanoma amenable to intratumoral neo-adjuvant immunotherapy.
1 trial -
UC-IMM-2511/2512
Ningbo Cancer Hospital
METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas). META-1: Patients in first-line therapy for advanced metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) >50%, without EGFR/ ALK/ ROS1 mutations and irrespective of their histological subtype (squamous or non-squamous)
1 trial -
UC-SAR-2212_L-UteCIN
Ningbo Cancer Hospital
Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma
1 trial -
UC_0160/1406
Ningbo Cancer Hospital
Penis carcinoma
1 trial -
UID 4270
Istituto Gentili S.r.l.
Metastatic hormone receptor-positive/HER2-negative breast cancer
1 trial -
UKD-IKF-Double-T
The George Institute
relapsed/refractory Large B-Cell Lymphoma
1 trial -
UKT-IKF-DEPECA-1
The George Institute
locally advanced or metastatic penile squamous cell carcinoma
1 trial -
US-guided RFA
The First People's Hospital of Lianyungang
Liver Cancer
1 trial -
US-guided laser ablation for refractory neoplasms
The First People's Hospital of Lianyungang
Refractory Neoplasms
1 trial -
Ubamatamab
Regeneron UK Limited
Advanced/Metastatic Non-Small Cell Lung Cancer
1 trial -
Ubamatamab
Regeneron UK Limited
Recurrent Ovarian Cancer
1 trial -
Ubamatamab
Regeneron UK Limited
Ovarian Cancer
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Non-Hodgkins Lymphoma
2 trials -
Ublituximab
TG THERAPEUTICS, INC.
Follicular Lymphoma
1 trial -
Umbralisib
TG THERAPEUTICS, INC.
Marginal Zone Lymphoma
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.